molecules of the month


CRBN-based selective IKZF1/3 degrader

oral efficacy in lenalidomide-resist. xenograft

from phenotypic screen and optimization

J. Med. Chem., Mar. 4, 2020

Celgene, San Diego, CA

Structure of compound CC-92480
1 min read

CC-92480 (Celgene/Bristol Myers Squibb (BMS) oral in vivo CRBN-based selective IKZF1/3 degrader)

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: